DrugPatentWatch Database Preview
Metuchen Pharms Company Profile
» See Plans and Pricing
What is the competitive landscape for METUCHEN PHARMS, and what generic alternatives to METUCHEN PHARMS drugs are available?
METUCHEN PHARMS has one approved drug.
There are two US patents protecting METUCHEN PHARMS drugs.
There are fifty-three patent family members on METUCHEN PHARMS drugs in twenty-six countries and eleven supplementary protection certificates in eleven countries.
Summary for Metuchen Pharms
| International Patents: | 53 |
| US Patents: | 2 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Metuchen Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Metuchen Pharms | STENDRA | avanafil | TABLET;ORAL | 202276-003 | Apr 27, 2012 | RX | Yes | Yes | 7,501,409 | Start Trial | Y | Start Trial | |||
| Metuchen Pharms | STENDRA | avanafil | TABLET;ORAL | 202276-003 | Apr 27, 2012 | RX | Yes | Yes | 6,656,935 | Start Trial | Y | Y | Start Trial | ||
| Metuchen Pharms | STENDRA | avanafil | TABLET;ORAL | 202276-001 | Apr 27, 2012 | RX | Yes | No | 7,501,409 | Start Trial | Y | Start Trial | |||
| Metuchen Pharms | STENDRA | avanafil | TABLET;ORAL | 202276-001 | Apr 27, 2012 | RX | Yes | No | 6,656,935 | Start Trial | Y | Y | Start Trial | ||
| Metuchen Pharms | STENDRA | avanafil | TABLET;ORAL | 202276-002 | Apr 27, 2012 | RX | Yes | No | 7,501,409 | Start Trial | Y | Start Trial | |||
| Metuchen Pharms | STENDRA | avanafil | TABLET;ORAL | 202276-002 | Apr 27, 2012 | RX | Yes | No | 6,656,935 | Start Trial | Y | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for METUCHEN PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 50 mg, 100 mg and 200 mg | ➤ Subscribe | 2016-04-27 |
International Patents for Metuchen Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Israel | 148291 | Start Trial |
| Hungary | 0202795 | Start Trial |
| Brazil | PI0014526 | Start Trial |
| Australia | 767558 | Start Trial |
| Australia | 7311800 | Start Trial |
| Norway | 20021308 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Metuchen Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1219609 | SPC/GB13/071 | United Kingdom | Start Trial | PRODUCT NAME: AVANAFIL; REGISTERED: UK EU/1/13/841 20130621 |
| 1219609 | 2013/041 | Ireland | Start Trial | PRODUCT NAME: AVANAFIL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/13/841 20130613 |
| 1219609 | 1390047-7 | Sweden | Start Trial | PRODUCT NAME: AVANAFIL; REG. NO/DATE: EU/1/13/841 20130621 |
| 1219609 | 122013000096 | Germany | Start Trial | PRODUCT NAME: AVANAFIL UND SEINE PHARMAZEUTISCH ANNEHMBAREN SALZE; REGISTRATION NO/DATE: EU/1/13/841 20130621 |
| 1219609 | 476 | Finland | Start Trial | |
| 1219609 | CA 2013 00040 | Denmark | Start Trial | |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
